An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease

Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?

(2019) Francesco Panza et al.   ANNALS OF NEUROLOGY

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease

(2019) Bjoern O. Schelter et al.   JOURNAL OF ALZHEIMERS DISEASE

Tau-targeting therapies for Alzheimer disease

(2018) Erin E. Congdon et al.   Nature Reviews Neurology

Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT)

(2018) Youssra K. Al-Hilaly et al.   JOURNAL OF MOLECULAR BIOLOGY

Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease

(2018) Gary P. Morris et al.   ACTA NEUROPATHOLOGICA

Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years

(2018) Kevin A. Matthews et al.   Alzheimers & Dementia

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

(2017) Gordon K. Wilcock et al.   JOURNAL OF ALZHEIMERS DISEASE

Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking

(2017) Youssra K. Al-Hilaly et al.   JOURNAL OF MOLECULAR BIOLOGY

Tau-based therapies in neurodegeneration: opportunities and challenges

(2017) Chuanzhou Li et al.   NATURE REVIEWS DRUG DISCOVERY

DrugBank 5.0: a major update to the DrugBank database for 2018

(2017) David S Wishart et al.   NUCLEIC ACIDS RESEARCH

Potential mechanisms and implications for the formation of tau oligomeric strains

(2016) Julia E. Gerson et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

(2016) Francesco Panza et al.   Biomed Research International

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

(2015) Valeria Melis et al.   BEHAVIOURAL PHARMACOLOGY

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

(2015) Charles R. Harrington et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

(2015) Katja Hochgräfe et al.   Acta Neuropathologica Communications

The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology

(2014) María del Carmen Cárdenas-Aguayo et al.   ACS Chemical Neuroscience

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

(2014) Cliona Stack et al.   HUMAN MOLECULAR GENETICS

Mechanistic Basis of Phenothiazine-Driven Inhibition of Tau Aggregation

(2013) Elias Akoury et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Tau-aggregation inhibitor therapy for Alzheimer's disease

(2013) Claude M. Wischik et al.   BIOCHEMICAL PHARMACOLOGY

Improving Alzheimer’s disease phase II clinical trials

(2012) Barry D. Greenberg et al.   Alzheimers & Dementia

Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

(2012) Erin E. Congdon et al.   Autophagy

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

(2012) Kevin Mullane et al.   BIOCHEMICAL PHARMACOLOGY